Teva Fights Muddy Reputation With Positive Report
“The main conclusion of Brill’s report is that Teva makes a significant contribution to the economies of the countries where it operates, via both direct and indirect employment.”
MGA’s Alex Brill on CNBC’s Squawk Box
In anticipation of the December jobs report number being released later in the morning, Brill joins the morning news program to discuss his predictions that the number “will be right on the quarterly trend.”
MGA’a Alex Brill on Liberty & Justice for All
“I advocate and support a carbon tax, but not just blindly, not just any carbon tax. It is critically important that the carbon tax be revenue neutral. That at the time at which this policy is put in place its done in a matter in which the revenues expected to be generated from the carbon tax are used to reduce other taxes that are more distortionary. This is what we would call the principles of basic tax reform.”
MGA’s Alex Brill on CNBC’s Squawk Box
MGA’s Alex Brill on CNBC’s Squawk Box
On this episode of ‘Squawk Box,’ Brill discusses Bill Gate’s reaction to Senator Elizabeth Warren’s proposed wealth tax, as well as the capital gains tax.
New Belgium Brewery’s employees think like owners. Because they are.
Alex Brill was quoted in Fast Company for his research on tax policy effects on business:
“… [Brill] has found that employees in ESOPs “get better at the job, and instead of quitting as soon as they get skills, they stay and get more skills.” Companies with ESOPs require fewer managers, as AEI’s Brill discovered in his research, because workers are given more freedom and are better able to manage themselves.”
Employers Could Reap Substantial Savings Through Biosimilars, But Not Without Targeted Effort
“A new report from Matrix Global Advisors and the National Business Group on Health, sponsored by Boehringer Ingelheim, shows that employers could see substantial savings from biosimilars, but those savings won’t come without a concerted effort to encourage biosimilar use.”
Debate Over Whether Biologics Constitute Natural Monopolies Continues
“Peter B. Bach, MD, a well-known critic of high drug prices, along with Jennifer A. Ohn, MPH, Preston Atteberry, MD, and Mark Trusheim, MSc, first wrote in April that biosimilar competition is an economically inefficient way to achieve the goal of lower prices; the biosimilar environment is different than the one that exists in the generic marketplace for small-molecule drugs. These authors said, instead, that biosimilars are natural monopolies and as such need price regulation in order for them to succeed and for prices to come down.”
MGA’s Alex Brill on CNBC’s Squawk Box
“I think its a solid [GDP] number. Obviously the inventory piece creates a little bit of volatility and the investment numbers are a disappointment, but not a surprise. Overall we see a strong consumers. On the Fed, I would agree with Austin. What the Fed has to do now more than ever is try to block out the political noise, focus on the data and make the best call to boost their credibility or sustain their credibility.”
Conservative Thinkers Share Their Views for Biosimilars in a Post-ACA, BPCIA Landscape
“Would legislators take the opportunity to redo some parts of the BPCIA, if they had the chance? Both [Alex] Brill and Hayes said while that, too, is theoretically possible—such as shortening the period of patent exclusivity or changing other aspects of the patent dance—the danger is that it would then get stuck in the quagmire of politics.”
Shortened Exclusivity Could Save $31B
“Brand-name medicines’ market exclusivity periods have climbed an average of 2.2 years since the mid-1990s, steadily delaying the market arrival of generic rivals. Reversing that trend alone could save the U.S. health care system roughly $31.7 billion, according to a Matrix report commissioned by the Coalition for Affordable Prescription Drugs, a group of insurers, pharmacy benefit managers and large employers.”